July 29, 2024

Company
name:SanBio Co., Ltd.
(Code: 4592 TSE Growth)Name ofrepresentative:

Keita Mori, Representative Director andPresident

For inquiries,contact:

Yoshihiro Kakutani, Corporate Officer ofManagement Administration(Phone: 03-6264-3481)

Notice Concerning Notice of Allowance of New Patent for Cell Therapy
Using SB623 for Chronic Ischemic Stroke in the US
SanBio Co., Ltd. hereby provides on this matter as per the attached document.

July 29, 2024
SanBio Co., Ltd.

Notice Concerning Notice of Allowance of New Patent for Cell Therapy
Using SB623 for Chronic Ischemic Stroke in the US
SanBio Co., Ltd. (Head office: Tokyo, Representative Director and President: Keita Mori)
and its subsidiary SanBio, Inc. hereby announce that the US Patent and Trademark Officehas issued Notice of Allowance of the patent application SanBio, Inc. filed for its key
development product SB623 (INN: vandefitemcel) for the treatment of chronic ischemic
stroke on July 15, 2024.
Details of the patent which we have received Notice of Allowance is as below.
Name of invention:
Country of filing:
Patent application number:
Notice of allowance date:
Applicant:

CELL THERAPIES AND METHODS OF TREATMENT FOR
SMALL-VOLUME STROKEUSUS 17/664,856
July 15, 2024
SanBio, Inc. Mountain View, CA (US)The Notice of Allowance was issued for the patent application submitted based on the resultsof the Phase 2b clinical trial of SB623 in chronic ischemic stroke patients in the US (STR-02study). Additional analysis of the study indicated that among patients with an infarction
volume of 50cc or less (77 out of 163 patients), the percentage of patients that demonstrated
composite improvement in the Fugl-Meyer Motor Scale score was significantly higher in thetreatment group than in the sham surgery (control) group１. Based on the results of theadditional analysis, the Notice of Allowance was issued for the cell therapy using SB623 totreat chronic ischemic stroke patients with an infarction volume less than 50cc.
As part of its efforts to maximize corporate value, SanBio is focused on building andmaintaining its patent portfolio. The Notice of Allowance of the patent significantly will extend
the term of the use patent for SB623 for the treatment of chronic ischemic stroke in the US,the largest market.
With the Notice of Allowance, SanBio will continue exploring ways to expand the indicationsof SB623 to include chronic ischemic stroke. This matter will have only a minimal impact on
the financial performance of the current fiscal year.

About SanBio Group (SanBio Co., Ltd. and SanBio, Inc.)
SanBio Group is engaged in the regenerative cell medicine business, spanning research,development, manufacture, and sales of regenerative cell medicines. The Company mainly
focuses on diseases of the central nervous system that cannot be addressed by existing
medical and pharmaceutical products and for which there is a high unmet medical need. The
Company is headquartered in Tokyo, Japan and Oakland, California, and additional
information about SanBio Group is available at https://sanbio.com/en/
About Stroke
Stroke is a condition caused by a blood clot blocking a blood vessel in the brain, leading toinsufficient blood supply to brain cells. It is estimated that there are 6.85 million stroke
patients in the US2 and 1.19 million in Japan3. Early treatment and intervention are crucial,
as severe disabilities may become permanent once the condition enters the chronic phase.
Current treatments for stroke patients in the chronic phase include pharmacotherapy toprevent recurrence and rehabilitation. However, there are no drugs available that
fundamentally address and treat chronic motor function disorders caused by stroke,
indicating a high unmet medical need.
<References>1
For details, please see pg. 27 of the “Business Plan and Matters Concerning Growth
Potential,” released on April 25, 2024
2
Company analysis based on multiple sources3
The number of “Cerebral infarction” patients in Patient Survey 2020, the Ministry of Health,Labour and WelfareFor more information, contact:
SanBio Co., Ltd.
Management Administration
Email: info@sanbio.com